Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.21 Million USD | -76.86% |
| 2022 | 5.24 Million USD | 2081.49% |
| 2021 | 240.65 Thousand USD | 11.88% |
| 2020 | 215.09 Thousand USD | -65.13% |
| 2019 | 616.77 Thousand USD | 65.86% |
| 2018 | 371.86 Thousand USD | 937.28% |
| 2017 | 35.85 Thousand USD | 2.41% |
| 2016 | 35 Thousand USD | 141.05% |
| 2015 | 14.52 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 1.21 Million USD | -76.86% |
| 2023 Q2 | 203.61 Thousand USD | -20.55% |
| 2023 Q3 | 203.61 Thousand USD | 0.0% |
| 2023 Q4 | 178.67 Thousand USD | -12.25% |
| 2023 Q1 | 256.28 Thousand USD | -59.24% |
| 2022 Q1 | 361.07 Thousand USD | 360.3% |
| 2022 FY | 5.24 Million USD | 2081.49% |
| 2022 Q4 | 628.82 Thousand USD | -60.58% |
| 2022 Q3 | 1.59 Million USD | -10.49% |
| 2022 Q2 | 1.78 Million USD | 393.63% |
| 2021 FY | 240.65 Thousand USD | 11.88% |
| 2021 Q3 | 47.09 Thousand USD | -16.31% |
| 2021 Q2 | 56.27 Thousand USD | -4.35% |
| 2021 Q1 | 58.83 Thousand USD | -7.22% |
| 2021 Q4 | 78.44 Thousand USD | 66.55% |
| 2020 Q3 | 49.32 Thousand USD | 2.66% |
| 2020 Q2 | 48.05 Thousand USD | -11.51% |
| 2020 Q4 | 63.41 Thousand USD | 28.55% |
| 2020 Q1 | 54.3 Thousand USD | -51.01% |
| 2020 FY | 215.09 Thousand USD | -65.13% |
| 2019 Q3 | 154.59 Thousand USD | -18.07% |
| 2019 Q2 | 188.67 Thousand USD | 15.99% |
| 2019 Q1 | 162.66 Thousand USD | -25.9% |
| 2019 FY | 616.77 Thousand USD | 65.86% |
| 2019 Q4 | 110.84 Thousand USD | -28.3% |
| 2018 Q4 | 219.5 Thousand USD | 1201.64% |
| 2018 Q2 | 111.67 Thousand USD | 368.84% |
| 2018 Q1 | 23.81 Thousand USD | 57.06% |
| 2018 FY | 371.86 Thousand USD | 937.28% |
| 2018 Q3 | 16.86 Thousand USD | -84.9% |
| 2017 Q3 | 3975.00 USD | -15.44% |
| 2017 Q4 | 15.16 Thousand USD | 281.53% |
| 2017 FY | 35.85 Thousand USD | 2.41% |
| 2017 Q1 | 12 Thousand USD | 71.54% |
| 2017 Q2 | 4701.00 USD | -60.85% |
| 2016 Q1 | 7844.00 USD | 169.37% |
| 2016 Q4 | 7000.00 USD | -53.33% |
| 2016 Q3 | 15 Thousand USD | 190.47% |
| 2016 Q2 | 5164.00 USD | -34.17% |
| 2016 FY | 35 Thousand USD | 141.05% |
| 2015 FY | 14.52 Thousand USD | 0.0% |
| 2015 Q2 | 2034.00 USD | 0.0% |
| 2015 Q3 | 3820.00 USD | 87.81% |
| 2015 Q4 | 2912.00 USD | -23.77% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -83.701% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 86.894% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 95.95% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 98.191% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 92.333% |
| Better Therapeutics, Inc. | 38.26 Million USD | 96.825% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 97.015% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 90.198% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 96.411% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 96.471% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 98.88% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -22.349% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 96.273% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 97.413% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 93.908% |
| Molecular Templates, Inc. | 63.09 Million USD | 98.075% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 91.281% |
| NexImmune, Inc. | 28.16 Million USD | 95.688% |
| Orgenesis Inc. | 45.75 Million USD | 97.345% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 95.264% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -1554.528% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 92.477% |
| Scopus BioPharma Inc. | 11.71 Million USD | 89.631% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 99.699% |
| Statera Biopharma, Inc. | 28.82 Million USD | 95.787% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 93.583% |
| Trevena, Inc. | 38.41 Million USD | 96.838% |
| Vaxxinity, Inc. | 56.05 Million USD | 97.833% |
| Vaccinex, Inc. | 23.45 Million USD | 94.821% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -16.018% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 97.604% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 83.302% |